Rechercher des projets européens

30 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet

 25

 EN COURS 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Voir le projet

 27

 TERMINÉ 

Sorting of Self (SOS)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

During inflammation and infection, we are simultaneously confronted with both self and non-self in form of dying cells and microbes, respectively. Mechanisms that facilitate the non-immunogenic clearance of self-antigens derived from apoptotic and necrotic cells and that, in parallel, allow the initiation of an immune response against invading pathogens are incompletely understood. Recent data fro ...
Voir le projet

 1

 TERMINÉ 

Pathogen and Graphene (PANG)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Complications related to infectious diseases have significantly reduced, particularly in the developed countries, due to the availability and use of broad-range antibiotics and wide variety of antimicrobial agents. Excessive use of antibiotics and antimicrobial agents increased significantly the number of multi-drug resistant (MDR) bacteria. This has resulted in a serious threat to public health. ...
Voir le projet

 8

 TERMINÉ 
We are proposing a four-year programme of knowledge transfer and networking between Aston University (ASTON, UK), Universitatsklinikum Erlangen (UKER, Germany) and Redoxis AB (Redoxis, Sweden). Our proposal targets an emerging area of biology, i.e. reactive oxygen species (ROS)-mediated regulation of immune responses; it brings together the application of small molecule candidate drugs to generate ...
Voir le projet

 3

 TERMINÉ 

Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit (CloSed)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,

The majority of critically ill children admitted to Paediatric Intensive Care Units (PICU) will require sedation and analgesia which is commonly achieved with a combination of an benzodiazepine and an opioid. However, these agents have a significant side-effect profile, including tolerance, withdrawal and respiratory/circulatory depression. Clonidine is commonly used for sedation in PICU and recom ...
Voir le projet

 10

 TERMINÉ 
Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet

 19

 TERMINÉ 
Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases. In addition, of the 600 new cases of ES o ...
Voir le projet

 21

 TERMINÉ 
DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cogni ...
Voir le projet

 29

 TERMINÉ 

MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy (EPIMIRNA)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling p ...
Voir le projet

 19

 TERMINÉ 
Tertiary sector buildings sector consume a sizeable proportion of EU total energy consumption and the majority of consumption is directly attributed to the operational phase of the building life-cycle. Occupant behaviour is a major cause of this consumption. OrbEEt proposes an ICT-based framework to induce behaviour change toward energy efficiency by transforming energy measurements into personali ...
Voir le projet

 10

 TERMINÉ 
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Voir le projet

 17

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

GAbapentin in Paediatric Pain (GAPP)

Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,

Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL.To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few ...
Voir le projet

 16

 TERMINÉ 

Open Project for the European Radiation Research Area (OPERRA)

Date du début: 1 juin 2013, Date de fin: 31 mai 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Voir le projet

 71

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 
An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early ...
Voir le projet

 17

 TERMINÉ 

DEferiprone Evaluation in Paediatrics (DEEP)

Date du début: 1 janv. 2011, Date de fin: 31 août 2016,

"β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood transfusions combined with chelating therapy to remove harmful iron accumulation in the body. The use of deferoxamine, the first chelating agent only available for subcutaneous administration is limited due to toxicity and the lack of compliance, despite its sat ...
Voir le projet

 18

 TERMINÉ 
Inflammatory rheumatic diseases affect millions of European citizens causing chronic pain, disability and premature death. Curative treatments are lacking. Conventional research often focuses on one single organ system such as the bone or the immune system and. ignores interactions between organ systems. OSTEOIMMUNE is a supra-disciplinary training network that targets this gap by providing compre ...
Voir le projet

 12

 TERMINÉ 
Chronic inflammatory diseases associated with allergy, including asthma and rhinitis, constitute a major and continuously growing public health concern for Europe. However, the causative factors and mechanisms converting a physiological inflammatory reaction to a chronic response triggering allergic disease remain elusive.Viral infections, particularly those caused by human rhinoviruses (RV) are t ...
Voir le projet

 13

 TERMINÉ 

Low Dose Research towards Multidisciplinary Integration (DOREMI)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

The aim of DoReMi is to promote the sustainable integration of low dose risk research in Europe in order to aid the effective resolution of the key policy questions identified by the High Level Expert Group (HLEG) on Low Dose Risk Research (www.hleg.de). DoReMi provides an operational tool for the development of the proposed MELODI platform (Multidisciplinary European Low Dose Risk Re-search Initi ...
Voir le projet

 39

 TERMINÉ 

Systems biology towards novel chronic kidney disease diagnosis and treatment (SysKID)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,

Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems ...
Voir le projet

 30

 TERMINÉ 

Persistence of allergic sensitization (PAS)

Date du début: 1 déc. 2009, Date de fin: 30 nov. 2014,

"Allergic disorders are dramatically increasing in the western world over the past several years. Allergies are inappropriate immune responses directed against harmless environmental antigens. Upon primary allergen encounter B cells are induced to differentiate into IgE producing plasma cells. Mast cells and basophils are then sensitized by binding of allergen-specific IgE molecules to the high-af ...
Voir le projet

 2

 TERMINÉ 
The eHealthMonitor project provides a platform that generates a Personal eHealth Knowledge Space (PeKS) as an aggregation of all knowledge sources (e.g., EHR and PHR) relevant for the provision of individualized personal eHealth services. This is realised by integrating service-oriented architecture, knowledge engineering, multiagent systems, and wearable/portable devices technologies. Innovations ...
Voir le projet

 11

 TERMINÉ 

Influence of protein prenylation and its modulation on the immune system (Pren-IBD)

Date du début: 1 août 2012, Date de fin: 31 juil. 2014,

Prenylation is a postranslational process leading to changes in protein structure due to the incorporation of a lipidic moiety that significantly modifies their physicochemical properties and their behaviour. Prenylation is therefore a crucial step for key cell processes, such as interaction between proteins, cell and differentiation, cytoskeletal function and vesicular trafficking. The modificati ...
Voir le projet

 1

 TERMINÉ 

ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS (ADIPOA)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2014,

Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown that intraarticular injections of stromal cells prevents OA in two different models, but the mechanisms of this chondroprotective effect remains unknown, and the activation of cartilage derived endogenous stem cells is suspected. The participants have experien ...
Voir le projet

 12

 TERMINÉ 
"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

European Network for Cell Imaging and Tracking Expertise (ENCITE)

Date du début: 1 juin 2008, Date de fin: 30 nov. 2012,

"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Voir le projet

 30

 TERMINÉ 
"GENINCA will address two tumor entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature: colorectal and liver cancer. Colorectal cancer amounts to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most com ...
Voir le projet

 14